Skip to main content

Advertisement

SpringerLink
Log in

The effect of bevacizumab on colon anastomotic healing in rats

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

The aim of the study was to investigate the effect of angiogenesis inhibition by bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF) antibody, on the healing process of colonic anastomoses in rats, assessing some specific involved factors. This new agent is used mainly in metastatic colorectal cancer. The angiogenesis plays an important role in both wound healing and metastatic invasion and spread of malignant cells. There has not been any evidence assessing the optimal time for its safe use in operated patients.

Materials and methods

Forty Wistar rats were randomly allocated into four equal groups. A colonic anastomosis was performed in all rats. Half of them received intraoperatively a single dose of bevacizumab 5 mg/body weight and the rest received placebo. The animals were sacrificed on the 7th (Avastin 7th, placebo 7th) and 14th (Avastin 14th, placebo1 4th) postoperative day. The anastomosis was resected and sent for histological study and for tissue biochemical assays (VEGF, endothelin-1 (ET-1), C-reactive protein (CRP), pro-oxidant–antioxidant balance (PAB), carbonylated proteins, hydroxyproline) using specific enzyme-linked immunosorbent assay kits. For statistical analysis, the Mann–Whitney U test was used (of statistical significance when P < 0.05).

Results

No complication or anastomotic dehiscence was observed. Histology did not reveal statistically significant differences between groups concerning degree of inflammation, fibroblasts, collagen, and fibrosis. Likewise, hydroxyproline levels did not differ. However, some statistically significant differences were found in VEGF, CRP and carbonyl proteins (Avastin 7th vs placebo 7th, placebo 14th vs placebo 7th), ET-1, and PAB (Avastin 14th vs Avastin 7th), which did not finally affect the collagen synthesis marker hydroxyproline, nor did the anastomotic strength.

Conclusions

Bevacizumab, when administered intraoperatively, has no significant effect on colon anastomotic healing in rats despite a transient mild ischemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. McWilliams RR, Erlichman C (2005) Novel therapeutics in colorectal cancer. Dis Colon Rectum 48:1632–1650

    Article  PubMed  Google Scholar 

  2. Thornton AD, Ravn P, Winslet M et al (2006) Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg 93:1456–1463

    Article  CAS  PubMed  Google Scholar 

  3. Krämer I, Lipp HP (2007) Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 32:1–14

    Article  PubMed  Google Scholar 

  4. McCormack PL, Keam SJ (2008) Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs 68:487–506

    Article  CAS  PubMed  Google Scholar 

  5. Kocakova I, Kocak I, Savoboda M et al (2009) Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer. Klin Onkol 22:73–76

    CAS  PubMed  Google Scholar 

  6. Shord SS, Bressler LR, Tierney LA et al (2009) Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 66:999–1013

    Article  CAS  PubMed  Google Scholar 

  7. Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830–1835

    Article  CAS  PubMed  Google Scholar 

  8. Brostjan C, Gebbardt K, Gruenberger B et al (2008) Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenetic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 14:2065–2074

    Article  CAS  PubMed  Google Scholar 

  9. Andre T, Tournigand C, Abbas F, et al (French Oncology Research Group) (2007). Anti-angiogenic treatment and colorectal cancer. Bull Cancer 94 Spec No: S211–S219.

  10. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779–1802

    Article  CAS  PubMed  Google Scholar 

  11. Salesi N, Bossone G, Veltri E et al (2005) Clinical experience with bevacizumab in colorectal cancer. Anticancer Res 25:3619–3623

    CAS  PubMed  Google Scholar 

  12. Normanno N, Morabito A, De Luca A et al (2009) Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 16(3):675–702

    Article  CAS  PubMed  Google Scholar 

  13. Denduluri N, Yang SX, Berman AW et al (2008) Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 7:15–20

    Article  CAS  PubMed  Google Scholar 

  14. Tao X, Sood AK, Deavers MT et al (2009) Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulose cell tumours. Gynecol Oncol 114(3):431–436

    Article  CAS  PubMed  Google Scholar 

  15. Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76–82

    Article  CAS  PubMed  Google Scholar 

  16. Abel EJ, Wood CG (2009) Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 6(7):375–383

    Article  CAS  PubMed  Google Scholar 

  17. Rossi A, Maione P, Colantuoni G et al (2009) Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol 6:91–102

    Article  CAS  PubMed  Google Scholar 

  18. Seong HK, Bae JH, Kim ES et al (2009) Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short term effect. Ophthalmologica 223:343–347

    Article  CAS  PubMed  Google Scholar 

  19. Chilov MN, Grigg JR, Playfair TJ (2007) Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 35:494–496

    Article  PubMed  Google Scholar 

  20. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788–1795

    Article  CAS  PubMed  Google Scholar 

  21. Knightly JJ, Agostino D, Cliffton EE (1962) The effect of fibrinolysin and heparin on the formation of peritoneal adhesions. Surgery 52:250

    CAS  PubMed  Google Scholar 

  22. Konstantinidis H, Slavakis A, Ballas K et al (2007) The effect of capecitabine on the healing of colonic anastomosis in rats. Dis Colon Rectum 50:89

    Article  PubMed  Google Scholar 

  23. Alamdari DH, Ghayour-Mobarhan M, Tavallaie S et al (2008) Prooxidant–antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem 41:375–380

    Article  CAS  PubMed  Google Scholar 

  24. Alamdari DH, Paletas K, Pegiou T et al (2007) A novel assay for the evaluation of the prooxidant–antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 40:248–254

    Article  CAS  PubMed  Google Scholar 

  25. Alamdari DH, Kostidou E, Paletas K et al (2005) High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic Biol Med 39:1362–1367

    Article  CAS  PubMed  Google Scholar 

  26. Reddy GK, Enwemeka CS (1996) A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29:225–229

    Article  CAS  PubMed  Google Scholar 

  27. Efron DT, Most D, Shi HP et al (2003) Modulation of growth factor and cytokine expression by nitric oxide during rat colon anastomotic healing. J Gastrointest Surg 7:393–399

    Article  PubMed  Google Scholar 

  28. Brasken P, Lehto M, Renvall S (1990) Fibronectin, laminin, and collagen types I, III, IV and V in the healing rat colon anastomosis. Ann Chir Gynaecol 79:65–71

    CAS  PubMed  Google Scholar 

  29. Brasken P, Renvall S, Sandberg M (1991) Fibronectin and collagen gene expression in healing experimental colonic anastomoses. Br J Surg 78:1048–1052

    Article  CAS  PubMed  Google Scholar 

  30. Podolsky DK (1997) Healing the epithelium: solving the problem from two sides. J Gastroenterol 32:122–126

    Article  CAS  PubMed  Google Scholar 

  31. Murphy MS (1998) Growth factors and the gastrointestinal tract. Nutrition 14:771–774

    Article  CAS  PubMed  Google Scholar 

  32. Thornton FJ, Barbul A (1997) Healing in the gastrointestinal tract. Surg Clin North Am 77:549–573

    Article  CAS  PubMed  Google Scholar 

  33. Kingham TP, Pachter HL (2009) Colonic anastomotic leak: risk factors, diagnosis and treatment. Am Coll Surg 208:269–278

    Article  Google Scholar 

  34. Guzman-de la Garza FJ, Camara-Lemarroy CR, Alarcon-Galvan G et al (2009) Different patterns of intestinal response to injury after arterial, venous or arteriovenous occlusion in rats. World J Gastroenterol 15:3901–3907

    Article  PubMed  Google Scholar 

  35. Fedorova M, Kuleva N, Hoffmann R (2009) Reversible and irreversible modifications of skeletal muscle proteins in a rat model of acute oxidative stress. Biochim Biophys Acta 1792(12):1185–1193

    CAS  PubMed  Google Scholar 

  36. Lee JJ, Chu E (2007) An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 13:276–281

    Article  CAS  PubMed  Google Scholar 

  37. Moehler M, Sprinzi MF, Abdelfattah M et al (2009) Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 15:449–456

    Article  CAS  PubMed  Google Scholar 

  38. Gordon CR, Rojavin Y, Patel M et al (2009) A review on bevacizumab and surgical wound healing. An important warning to all surgeons. Ann Plast Surg 62:707–709

    Article  CAS  PubMed  Google Scholar 

  39. Scappaticci FA, Fehrenbacher L, Cartwright T et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Clin Oncol 91:173–180

    CAS  Google Scholar 

  40. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta- analysis. Lancet Oncol 10:559–568

    Article  CAS  PubMed  Google Scholar 

  41. Raatschen HJ, Fu Y, Brasch RC, Pietsch H, Shames DM, Yeh BM (2009) In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol 44:265–270

    Article  CAS  PubMed  Google Scholar 

  42. Hsei V, DeGuzman GG, Nixon A, Gaudreault J (2002) Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res 19:1753–1756

    Article  CAS  PubMed  Google Scholar 

  43. Mizobe T, Ogata Y, Murakami H, Akagi Y, Ishibashi N, Mori S, Sasatomi T, Shirouzu K (2008) Efficacy of the combined use of bevacizumab and irinotecan as postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep 20:517–523

    CAS  PubMed  Google Scholar 

  44. Igniatovic D, Aasland K, Pettersen M, Sund S, Chen Y, Spasojevic M, Nesgaard JM (2010). Intra-abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg 200:270–275

    Google Scholar 

  45. Blouhos K, Pramateftakis MG, Tsachalis T, Kanellos D, Zaraboukas T, Koliakos G, Betsis D (2010) The integrity of colonic anastomoses following the intraperitoneal administration of oxaliplatin. Int J Colorectal Dis 25:835–841

    Article  PubMed  Google Scholar 

  46. Uludag M, Ozdilli K, Citgez B, Yetkin G, Ipcioglu OM, Ozcan O, Polat N, Kartal A, Torun P, Isgor A (2010) Covering the colon anastomoses with amniotic membrane prevents the negative effects of early intraperitoneal 5-FU administration on anastomotic healing. Int J Colorectal Dis 25:223–232

    Article  PubMed  Google Scholar 

  47. Benjamin B, Hazut O, Shaashua L, Benish M, Zmora N, Barshack I, Hoffman A, Ben-Eliyahu S, Zmora O (2010). Effect of beta-blocker combined with COX-2 inhibitor on colonic anastomosis in rats. Int J Colorectal Dis. doi:10.1007/s00384-010-0992-8

Download references

Author information

Authors and Affiliations

  1. Second Propedeutical Department of Surgery, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Konstantinoupoleos 49, 546 42, Thessaloniki, Greece

    Efstathios T. Pavlidis, Konstantinos D. Ballas, Nikolaos G. Symeonidis, Kyriakos Psarras, Savas F. Rafailidis, Theodoros E. Pavlidis, Georgios N. Marakis & Athanasios K. Sakantamis

  2. Laboratory of Biological Chemistry, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Georgios Koliakos & Konstantina Topouridou

  3. Laboratory of Histology–Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Kokona Kouzi-Koliakos

  4. A Samothraki 23, 542 48, Thessaloniki, Greece

    Theodoros E. Pavlidis

Authors
  1. Efstathios T. Pavlidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konstantinos D. Ballas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikolaos G. Symeonidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyriakos Psarras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georgios Koliakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kokona Kouzi-Koliakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Konstantina Topouridou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Savas F. Rafailidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Theodoros E. Pavlidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Georgios N. Marakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Athanasios K. Sakantamis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodoros E. Pavlidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pavlidis, E.T., Ballas, K.D., Symeonidis, N.G. et al. The effect of bevacizumab on colon anastomotic healing in rats. Int J Colorectal Dis 25, 1465–1473 (2010). https://doi.org/10.1007/s00384-010-1039-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-010-1039-x

Keywords

Search

Navigation